Table 2. Level of strength-of-evidence of HIV infection/AIDS in 171 cancer cases that were registered.
HIV Serology | |||||
Level Strength-of-Evidence | Total(n = 171) | Initial HIV(+) Serology (n = 25) | Subsequent ConfirmedHIV(+) Serology (n = 22) | Total HIV(+)Serology | Clinical CriteriaOnly (n = 24) |
Any CD4+ lymphocyte countCD4+ count <350/µL | 48 (28%)30 (18%) | 7 (28%)2 (8%) | 13 (37%)8 (36%) | 20 (33%)10 (21%) | 28 (23%)20 (16%) |
Any antiretroviral (cARV) therapySpecific cARV regimenRegimen not specified | 87 (51%)38 (22%)49 (29%) | 12 (48%)3 (12%)9 (36%) | 16 (73%)13 (59%)3 (14%) | 28 (60%)16 (34%)12 (26%) | 59 (48%)22 (18%)*37 (30%) |
WHO clinical stage and/or ISSin medical record | 171 (100%) | 25 (100%) | 22 (100%) | 47 (100%) | 124 (100%) |
Of the subsequent confirmed HIV(+) serology 12 were identified at the Comprehensive Care Clinic and 10 at the Department of Radiation Oncology at Kenyatta National Hospital. [Notes: *Statistically significant difference (p = 0.022) between positive serology group (n = 47) and clinical criteria only group (n = 124) with respect to the level strength-of-evidence (Chi-square test)].